Lei Kang1,2, Dawei Jiang2,3, Christopher G England4, Todd E Barnhart4, Bo Yu2, Zachary T Rosenkrans5, Rongfu Wang1, Jonathan W Engle4, Xiaojie Xu6, Peng Huang7, Weibo Cai8,9,10,11. 1. Department of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, China. 2. Department of Radiology, University of Wisconsin - Madison, Madison, WI, 53705, USA. 3. Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, Laboratory of Evolutionary Theranostics, School of Biomedical Engineering, Health Science Center, Shenzhen University, Nanhai Ave 3688, Shenzhen, 518060, China. 4. Department of Medical Physics, University of Wisconsin - Madison, Madison, WI, 53705, USA. 5. School of Pharmacy, University of Wisconsin - Madison, Madison, WI, 53705, USA. 6. Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing, 100850, China. miraclexxj@126.com. 7. Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, Laboratory of Evolutionary Theranostics, School of Biomedical Engineering, Health Science Center, Shenzhen University, Nanhai Ave 3688, Shenzhen, 518060, China. peng.huang@szu.edu.cn. 8. Department of Radiology, University of Wisconsin - Madison, Madison, WI, 53705, USA. wcai@uwhealth.org. 9. Department of Medical Physics, University of Wisconsin - Madison, Madison, WI, 53705, USA. wcai@uwhealth.org. 10. School of Pharmacy, University of Wisconsin - Madison, Madison, WI, 53705, USA. wcai@uwhealth.org. 11. University of Wisconsin Carbone Cancer Center, Madison, WI, 53705, USA. wcai@uwhealth.org.
Abstract
PURPOSE: CD38 is considered a potential biomarker for multiple myeloma (MM) and has shown a strong link with chronic lymphocytic leukemia due to high and uniform expression on plasma cells. In vivo evaluation of CD38 expression may provide useful information about lesion detection and prognosis of treatment in MM. In this study, immunoPET imaging with 89Zr-labeled daratumumab was used for differentiation of CD38 expression in murine lymphoma models to provide a potential non-invasive method for monitoring CD38 in the clinic. METHODS: Daratumumab was radiolabeled with 89Zr (t1/2 = 78.4 h) via conjugation with desferrioxamine (Df). After Western blot (WB) was used to screen CD38 expression in five lymphoma cell lines, flow cytometry and cellular binding assays were performed to test the binding ability of labeled or conjugated daratumumab with CD38 in vitro. PET imaging and biodistribution studies were performed to evaluate CD38 expression after injection of 89Zr-Df-daratumumab. 89Zr-Df-IgG was also evaluated as a non-specific control group in the Ramos model. Finally, CD38 expression in tumor tissues was verified by histological analysis. RESULTS: Using WB screening, the Ramos cell line was found to express the highest level of CD38 while the HBL-1 cell line had the lowest expression. Df-conjugated and 89Zr-labeled daratumumab displayed similar high binding affinities with Ramos cells. PET imaging of 89Zr-Df-daratumumab showed a high tumor uptake of up to 26.6 ± 8.0 %ID/g for Ramos at 120 h post-injection, and only up to 6.6 ± 2.9 %ID/g for HBL-1 (n = 4). Additionally, 89Zr-Df-IgG demonstrated a low tumor uptake in the Ramos model (only 4.3 ± 0.8 %ID/g at 120 h post-injection). Ex vivo biodistribution studies showed similar trends with imaging results. Immunofluorescence staining of tumor tissues verified higher CD38 expression of Ramos than that of HBL-1. CONCLUSIONS: The role of 89Zr-Df-daratumumab was investigated for evaluating CD38 expression in lymphoma models non-invasively and was found to be to a promising imaging agent of CD38-positive hematological diseases such as MM in future clinical applications.
PURPOSE:CD38 is considered a potential biomarker for multiple myeloma (MM) and has shown a strong link with chronic lymphocytic leukemia due to high and uniform expression on plasma cells. In vivo evaluation of CD38 expression may provide useful information about lesion detection and prognosis of treatment in MM. In this study, immunoPET imaging with 89Zr-labeled daratumumab was used for differentiation of CD38 expression in murinelymphoma models to provide a potential non-invasive method for monitoring CD38 in the clinic. METHODS:Daratumumab was radiolabeled with 89Zr (t1/2 = 78.4 h) via conjugation with desferrioxamine (Df). After Western blot (WB) was used to screen CD38 expression in five lymphoma cell lines, flow cytometry and cellular binding assays were performed to test the binding ability of labeled or conjugated daratumumab with CD38 in vitro. PET imaging and biodistribution studies were performed to evaluate CD38 expression after injection of 89Zr-Df-daratumumab. 89Zr-Df-IgG was also evaluated as a non-specific control group in the Ramos model. Finally, CD38 expression in tumor tissues was verified by histological analysis. RESULTS: Using WB screening, the Ramos cell line was found to express the highest level of CD38 while the HBL-1 cell line had the lowest expression. Df-conjugated and 89Zr-labeled daratumumab displayed similar high binding affinities with Ramos cells. PET imaging of 89Zr-Df-daratumumab showed a high tumor uptake of up to 26.6 ± 8.0 %ID/g for Ramos at 120 h post-injection, and only up to 6.6 ± 2.9 %ID/g for HBL-1 (n = 4). Additionally, 89Zr-Df-IgG demonstrated a low tumor uptake in the Ramos model (only 4.3 ± 0.8 %ID/g at 120 h post-injection). Ex vivo biodistribution studies showed similar trends with imaging results. Immunofluorescence staining of tumor tissues verified higher CD38 expression of Ramos than that of HBL-1. CONCLUSIONS: The role of 89Zr-Df-daratumumab was investigated for evaluating CD38 expression in lymphoma models non-invasively and was found to be to a promising imaging agent of CD38-positive hematological diseases such as MM in future clinical applications.
Authors: Michel de Weers; Yu-Tzu Tai; Michael S van der Veer; Joost M Bakker; Tom Vink; Daniëlle C H Jacobs; Lukas A Oomen; Matthias Peipp; Thomas Valerius; Jerry W Slootstra; Tuna Mutis; Wim K Bleeker; Kenneth C Anderson; Henk M Lokhorst; Jan G J van de Winkel; Paul W H I Parren Journal: J Immunol Date: 2010-12-27 Impact factor: 5.422
Authors: Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe Journal: Blood Date: 2016-03-15 Impact factor: 22.113
Authors: S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel Journal: Blood Date: 2011-02-03 Impact factor: 22.113
Authors: Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie Journal: Blood Date: 2009-05-14 Impact factor: 22.113
Authors: Marije B Overdijk; J H Marco Jansen; Maaike Nederend; Jeroen J Lammerts van Bueren; Richard W J Groen; Paul W H I Parren; Jeanette H W Leusen; Peter Boross Journal: J Immunol Date: 2016-06-17 Impact factor: 5.422
Authors: Esther G M de Waal; Andor W J M Glaudemans; Carolien P Schröder; Edo Vellenga; Riemer H J A Slart Journal: Eur J Nucl Med Mol Imaging Date: 2016-11-29 Impact factor: 9.236
Authors: Lei Kang; Cuicui Li; Zachary T Rosenkrans; Jonathan W Engle; Rongfu Wang; Dawei Jiang; Xiaojie Xu; Weibo Cai Journal: J Nucl Med Date: 2020-08-21 Impact factor: 10.057
Authors: Shiyong Li; Christopher G England; Emily B Ehlerding; Christopher J Kutyreff; Jonathan W Engle; Dawei Jiang; Weibo Cai Journal: Am J Transl Res Date: 2019-09-15 Impact factor: 4.060
Authors: Gary A Ulaner; Nicholas B Sobol; Joseph A O'Donoghue; Assen S Kirov; Christopher C Riedl; Ryan Min; Eric Smith; Lukas M Carter; Serge K Lyashchenko; Jason S Lewis; C Ola Landgren Journal: Radiology Date: 2020-04-07 Impact factor: 11.105
Authors: Miao Li; Dawei Jiang; Todd E Barnhart; Tianye Cao; Jonathan W Engle; Weiyu Chen; Weibo Cai Journal: Am J Cancer Res Date: 2019-09-01 Impact factor: 6.166
Authors: Lei Kang; Cuicui Li; Zachary T Rosenkrans; Nan Huo; Zhao Chen; Emily B Ehlerding; Yan Huo; Carolina A Ferreira; Todd E Barnhart; Jonathan W Engle; Rongfu Wang; Dawei Jiang; Xiaojie Xu; Weibo Cai Journal: Adv Sci (Weinh) Date: 2021-03-15 Impact factor: 16.806
Authors: Cuicui Li; Lei Kang; Kevin Fan; Carolina A Ferreira; Kaelyn V Becker; Nan Huo; Hanxiao Liu; Yunan Yang; Jonathan W Engle; Rongfu Wang; Xiaojie Xu; Dawei Jiang; Weibo Cai Journal: Bioconjug Chem Date: 2021-01-21 Impact factor: 6.069